13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001819257
Total reported value
$645.5M
$645.5M
19 檔
33.8%
At the close of Q2 2025, Patient Square Capital LP disclosed equity holdings valued at approximately $645.5M, spread across 19 reported holdings.
In Q2 2025, Patient Square Capital LP adopted a defensive or profit-taking posture, trimming 10 positions and completely liquidating 3 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 50.71% | +3.84% | — | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 13.02% | -4.57% | EXIT | |
| 3 | ARGX | Argenx Se - Adr | Stock-Healthcare | 5.76% | -1.45% | — | |
| 4 | EYPT | Eyepoint Inc | Stock-Other | 4.59% | -0.22% | -8.71% | |
| 5 | LQDA | Liquidia CORP | Stock-Other | 4.58% | — | -33.00% | |
| 6 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.74% | — | -11.14% | |
| 7 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 2.36% | — | -1.14% | |
| 8 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.20% | -0.64% | -1.55% | |
| 9 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.08% | +0.95% | -2.49% | |
| 10 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.97% | — | — | |
| 11 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.78% | +0.28% | -3.15% | |
| 12 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.69% | — | -7.82% | |
| 13 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.68% | — | — | |
| 14 | PHVS | Pharvaris N.V. | Stock-Other | 1.55% | +1.13% | -0.49% | |
| 15 | IRON | Disc Medicine Inc | Stock-Other | 1.41% | — | -10.84% | |
| 16 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.07% | +0.14% | +11.27% | |
| 17 | GERN | Geron CORP | Stock-Other | 0.36% | — | — | |
| 18 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.26% | — | — | |
| 19 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.19% | — | +23.34% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | +5.8% | NEW | New buy |
| 2 | INSM | Insmed Inc | +2.6% | +8.64% | Add |
| 3 | EYPT | Eyepoint Inc | +1.3% | -8.71% | Trim |
| 4 | KYMR | Kymera Therapeutics Inc | +0.6% | -1.55% | Trim |
| 5 | GERN | Geron CORP | +0.4% | NEW | New buy |
| 6 | CDTX | Cidara Therapeutics Inc | +0.3% | NEW | New buy |
| 7 | VYNE | Vyne Therapeutics Inc | 0% | +23.34% | Add |
| 8 | AGIO | Agios Pharmaceuticals Inc | 0% | — | Unchanged |
| 9 | PHVS | Pharvaris N.V. | 0% | -0.49% | Trim |
| 10 | OCUL | Ocular Therapeutix Inc | -0.1% | -11.14% | Trim |
| 11 | SRRK | Scholar Rock Holding CORP | -0.1% | — | Unchanged |
| 12 | MIRM | Mirum Pharmaceuticals Inc | -0.1% | -2.49% | Trim |
| 13 | IRON | Disc Medicine Inc | -0.3% | -10.84% | Trim |
| 14 | ELVN | Enliven Therapeutics Inc | -0.3% | -3.15% | Trim |
| 15 | ALLO | Allogene Therapeutics Inc | -0.4% | +11.27% | Add |
| 16 | CGEM | Cullinan Therapeutics Inc | -0.4% | -1.14% | Trim |
| 17 | NRIX | Nurix Therapeutics Inc | -0.5% | -7.82% | Trim |
| 18 | SLNOEUR | Soleno Therapeutics Inc | -0.6% | EXIT | Sold out |
| 19 | NTLA | Intellia Therapeutics Inc | -0.7% | EXIT | Sold out |
| 20 | ROIV | Roivant Sciences Ltd. | -1.4% | — | Unchanged |
| 21 | 2655787D | Blueprint Medicines CORP | -1.4% | EXIT | Sold out |
| 22 | LQDA | Liquidia CORP | -4.7% | -33.00% | Trim |
According to official SEC Form 13F filings, Patient Square Capital LP reported a total U.S. public equity portfolio value of $645.5M across 19 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, INSM, ARGX) accounted for 33.8% of total reported equity market value during Q2 2025.
Top New Position Initiated
ARGX
市值: $16.0M
Top Position Liquidated / Trimmed
2655787D
前期市值: $3.4M
During Q2 2025, Patient Square Capital LP's top holdings by market value included ROIV (50.7%)、INSM (13.0%)、ARGX (5.8%). The largest single position, ROIV, represented 50.7% of total portfolio value.
In Q2 2025, Patient Square Capital LP made 19 total portfolio adjustments, initiating 3 new buys, adding to 3 positions, trimming 10 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.